Abstract 15P
Background
Although electrocautery is popularly used for the skin flap preparations at the time of mastectomy, we have been making the skin flap using the tumescent technique for the protects of the wound and skin flap since 2012 in our department. The aim of the study is to examine the differences of the clinical outcomes by between the surgeons (specialist who is familiar with breast surgery vs non-special surgeons).
Methods
166 patients who underwent the reconstruction after 1ststage of mastectomy with the tumescent technique at our hospital from March 2012 to December 2018 were enrolled. Tumescent technique; just before skin incision, we injected the tumescent solusions (200ml of physiological saline, 1mg of adrenaline, 20ml of xylocaine) subcutaneously into the breast and we started the sharp skin incision containing the tumor and around the areola like the spindle shape. If the tumor is close to the skin, we resected the skin just above tumor. We separated between subcutaneous and mammary tissue, and made the skin flap widely using the mechenbaum scissor and the wound retractor for protect the skin cutting edge. The most important things of this technique are to get the viewing field using the wound retractor with light and and the hemostasis exactly using McCannd forceps.
Results
patients characteristics is mean age 47.9 years (25-73 years), BMI is mean 21.1 (16.4-35.4), complication disease are 4 cases of hypertension, 4 cases of diabetes mellitus, 3 cases of radiotherapy previously, we performed surgery for 52 cases of DICS, for 114 cases of the invasive cancer including 10 cases of the axillary lymph node dissections, specialist performed 100 cases of mastectomy, on the other hand non-special surgeons performed 66 cases of mastectomy. Mean operation time is 56 min and 62 min (p = 0.314), there are no significant differences between the weight of the resected tissue and operation time (p = 0.062. Mean blood loss is 54ml each. 49 case (29%) of the mild necrosis of the skin, and 8 cases (4.7%) of hematoma were totally occurred after surgery, There are also no significant differences between specialist and non-special surgeons.
Conclusions
Mastectomy using the tumescent technique is easy and safe for not only specialist but also non-special surgeons.
Clinical trial identification
Editorial acknowledgement
Tissue expander and Inplants were approved for clinical use in Japan in July 2013.Since 2013, the reconstruction after mastectomy has been increasing year by year in Japan.
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
490P - Outcomes of sequential epidermal growth factor receptor tyrosine (EGFR) tyrosine kinase inhibitor (TKI) therapy in patients with advanced non-small cell lung carcinoma (NSCLC)- a real-world institutional experience
Presenter: Yvonne Ang
Session: Poster display session
Resources:
Abstract
498P - An observational retrospective study to evaluate the incidence of acquired EGFR T790M resistance in NSCLC patients with EGFR mutation following progression after at least one prior EGFR TKI treatment in Taiwan: ARISE study
Presenter: Shang-gin Wu
Session: Poster display session
Resources:
Abstract
501P - Clinical characteristics and efficacy in non-small cell lung cancer patients with EGFR exon 20 insertion and EGFR amplification
Presenter: Xin Gao
Session: Poster display session
Resources:
Abstract
502P - Epidermal growth factor receptor tyrosine kinase inhibitor treatment response in advanced non-small cell lung cancer with uncommon mutations: A multicenter observational study
Presenter: Masaki Kanazu
Session: Poster display session
Resources:
Abstract
482P - Interim analysis from a phase IIIb, open-label study of afatinib in EGFR TKI-naïve patients (pts) with EGFR mutation-positive (EGFRm+) NSCLC
Presenter: Filippo De Marinis
Session: Poster display session
Resources:
Abstract
483P - A phase IIIb, open-label study of afatinib in EGFR TKI-naïve patients with EGFR mutation-positive NSCLC: A biomarker analysis
Presenter: Rafael Rosell
Session: Poster display session
Resources:
Abstract
484P - Activity of afatinib in patients (pts) with EGFR mutation-positive (EGFRm+) NSCLC and baseline brain metastases: Pooled analysis of three large phase IIIb trials
Presenter: Maya Gottfried
Session: Poster display session
Resources:
Abstract
491P - Clinical outcomes of leptomeningeal metastases in EGFR-mutant lung adenocarcinoma
Presenter: Chia-I Shen
Session: Poster display session
Resources:
Abstract
510P - Paclitaxel as continuation maintenance therapy in patients with advanced non-small cell lung cancer
Presenter: Suzy Gohar
Session: Poster display session
Resources:
Abstract
496P - Higher osimertinib introduction rate achieved by multiple repeated re-biopsy after acquired resistance to first/second generation EGFR-TKIs
Presenter: Taira Ninomaru
Session: Poster display session
Resources:
Abstract